Skip to main content
Midas Edge

TELA Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

​​​​​​​​​​​​​​​​​​
​ · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Accumulated · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common stock · ​ · paid‑in · ​ · comprehensive · ​ · Accumulated · ​ · ​ · ​
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ ​ ​ · income · ​ ​ ​ · deficit · ​ ​ ​ · Total
Balance at January 1, 202319,165,027​$19​$288,361​$150​$(274,225)​$14,305
Vesting of restricted stock units and exercise of stock options126,987​—​127​—​—​127
Issuance of common stock under the employee stock purchase plan​10,602​—​88​—​—​88
Shares withheld for employee taxes​(27,131)​​—​​(289)​​—​​—​​(289)
Foreign currency translation adjustment—​​—​​—​​(59)​​—​(59)
Stock‑based compensation expense—​—​5,032​—​—​5,032
Sale of common stock, net of underwriting discounts, commissions and offering costs​5,219,190​​5​​46,336​​—​​—​​46,341
Net loss—​—​—​—​(46,664)​(46,664)
Balance at December 31, 202324,494,675​​24​​339,655​​91​​(320,889)—​18,881
Vesting of restricted stock units and exercise of stock options229,606​1​225​—​—​226
Issuance of common stock under the employee stock purchase plan​58,994​​—​​281​​—​​—​​281
Shares withheld for employee taxes​(57,563)​​—​​(369)​​—​​—​​(369)
Foreign currency translation adjustment—​—​—​(1)​—​(1)
Stock‑based compensation expense​—​​—​​4,362​​—​​—​​4,362
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs​14,670,000​​14​​42,905​​—​​—​​42,919
Net loss—​—​—​—​(37,841)​(37,841)
Balance at December 31, 202439,395,712​​39​​387,059​​90​​(358,730)​​28,458
Vesting of restricted stock units​279,765​​1​​—​​—​​—​​1
Issuance of common stock under the employee stock purchase plan​58,235​​—​​105​​—​​—​​105
Shares withheld for employee taxes​(84,448)​​—​​(205)​​—​​—​​(205)
Issuance of common stock warrants in connection with credit facility​—​​—​​1,413​​—​​—​​1,413
Exercise of pre-funded warrant​700,000​​—​​(1)​​—​​—​​(1)
Foreign currency translation adjustment​—​​—​​—​​1​​—​​1
Stock‑based compensation expense​—​​—​​3,796​​—​​—​​3,796
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs​4,189,000​​4​​11,572​​—​​—​​11,576
Net loss​—​​—​​—​​—​​(38,831)​​(38,831)
Balance at December 31, 2025​44,538,264​$44​$403,739​$91​$(397,561)​$6,313
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.